$ICUI

Merit Medical (MMSI) reported Q2 revenue growth of 9%, raising full-year guidance and seeing a 4.5% stock increase. ICU Medical (ICUI) reported flat revenue but beat EPS estimates, with a 2.1% stock decline. Penumbra (PEN) saw 14.9% revenue growth but missed EPS estimates, with a flat stock. Artivion (AORT) reported 11.3% revenue growth and beat EPS estimates, but its stock fell 19.2%.

Otsuka ICU Medical recalled a saline lot that may contain potassium chloride bags, marking the third such issue in 19 months. The FDA posted the recall, which affects 0.9% Sodium Chloride Injection, USP, 100 mL, lot 1042188. No injuries have been reported. The company has not linked the incidents, which involve the same product line.

ICU Medical Inc's (ICUI) VP and General Counsel Virginia Sanzone sold 4,856 shares at $168.69 each, totaling $819,000. She has sold 8,233 shares in the past year with no purchases. The company's stock has a P/E ratio of 140.92, higher than industry and historical averages. GuruFocus values the stock at $120.76, suggesting it is significantly overvalued.

ICU Medical's VP and General Counsel, Virginia Ruth Sanzone, sold 4,856 shares of common stock on September 3, 2026, under a Rule 10b5-1 trading plan adopted in June 2026. The sales occurred in four transactions at weighted average prices ranging from $167.67 to $171.52 per share, totaling approximately $819,000.

Sanzone Virginia Ruth (VP, General Counsel) sold 4,856 shares of ICU MEDICAL INC/DE (ICUI) at an average of $168.69 ($167.67–$171.52, $0.82M total) across 4 trades on 2026-09-03 under a Rule 10b5-1 trading plan.

Bonnell Brian Michael (Chief Financial Officer) sold 6,381 shares of ICU MEDICAL INC/DE (ICUI) at $175.00 ($1.12M total) on 2026-09-01 under a Rule 10b5-1 trading plan.

Bonnell Brian Michael (Chief Financial Officer) sold 9,307 shares of ICU MEDICAL INC/DE (ICUI) at an average of $172.79 ($171.05–$173.91, $1.61M total) across 4 trades on 2026-08-31 under a Rule 10b5-1 trading plan.

S&P Global Ratings upgraded ICU Medical Inc. to 'BB' from 'BB-', citing improved credit metrics and strong operating performance. The company's adjusted leverage decreased to 3.1x in Q2 2026, with free operating cash flow exceeding expectations. ICU Medical used proceeds from asset sales and cash flow to reduce debt. S&P projects mid-single-digit revenue growth and margin improvement through 2027, with a stable outlook based on expected debt and cash flow metrics.

ICU Medical (ICUI) reported Q2 2026 revenue of $551.7M, up 1% reported and 6% organic excluding IV Solutions divestiture and currency. Infusion Systems revenue was $189.0M (+12% organic), Consumables $289.3M (+5% organic). Adjusted EBITDA was $110.0M (+10%). Full-year guidance raised to $415M-$435M EBITDA and $8.60-$9.00 EPS.

Woolson Daniel (VP, GM-Infusion Capital) sold 5,417 shares of ICU MEDICAL INC/DE (ICUI) at $181.33 ($0.98M total) on 2026-08-13.